Highlights
Recently, according to the official website of CDE, the IND application of Shandong Gujin Traditional Chinese Medicine/Shandong University of Traditional Chinese Medicine for the treatment of hypertension was undertaken by Shandong Gujin Traditional Chinese Medicine/Shandong University of Traditional Chinese Medicine 1.1 new drug Vine ginseng antihypertensive granules. According to data from Minenet, in 2023, the sales of Chinese patent medicines for cardiovascular diseases in China's three major terminals and six major markets will exceed 51 billion yuan.
Vine ginseng antihypertensive granules is a new class 1 new drug of traditional Chinese medicine submitted for IND in the second paragraph of Shandong Gujin Traditional Chinese Medicine/Shandong University of Traditional Chinese Medicine, which is used for the treatment of hypertension. On May 27 this year, the first Category 1 new Chinese medicine drug of both parties, Chai Gui Jiegan Granules, was granted implicit approval for clinical trials for the treatment of acute upper respiratory tract infections.
According to data from Minenet, the Chinese patent medicine market for cardiovascular diseases has entered a period of adjustment in recent years, and in 2023, the sales volume of China's three major terminal and six major markets (see the end of this article for details) will exceed 51 billion yuan, a year-on-year increase of 4.75%.
Sales of proprietary Chinese medicines for cardiovascular diseases in China's three major terminals and six major markets (unit: 10,000 yuan)
Source: Minenet Grid Bureau Database
In 2023, the top 5 brands of Chinese patent medicines for cardiovascular diseases in China's three major terminal and six major markets are Tasly Pharmaceutical Group's compound Danshen Dripping Pill, Shanghai Hutchison Pharmaceutical's Musk Baoxin Pill, Shandong Buchang Pharmaceutical's Wenxin Granules, Beijing Yiling Pharmaceutical's Ginseng Song Yangxin Capsule, and Shijiazhuang Yiling Pharmaceutical's Tongxinluo Capsule.
In 2023, it will be the TOP5 brand of Chinese patent medicine for cardiovascular diseases in China's three major terminals and six major markets
Source: Minenet Grid Bureau Database
Shandong Gujin Traditional Chinese Medicine Technology Co., Ltd. is a small and medium-sized scientific and technological enterprise engaged in the research and development of new traditional Chinese medicine drugs in Jinan, Shandong Province, and the company has a number of new projects of traditional Chinese medicine.
In recent years, there have been domestic enterprises that have successively deployed Class 1 new drugs of antihypertensive traditional Chinese medicine, such as Ruiyang Pharmaceutical's Kidney Tonifying and Pulse Granules, Fujian University of Traditional Chinese Medicine's Qingda Granules, and Hangzhou Danhe Pharmaceutical's Dendrobium Chewable Tablets.
Source: Minenet database, CDE
Note: The statistical scope of "Drug Competition Pattern of China's Three Terminals and Six Major Markets" by Minenet is: urban public hospitals and county-level public hospitals, urban community centers and township health centers, urban physical pharmacies and online pharmacies, excluding private hospitals, private clinics, village clinics, and county and rural pharmacies; The above sales are calculated based on the average retail price of the product at the terminal.